Management of an Inappropriately Treated Case of Auricular Hematoma

Yoonjoong Kim¹, Jin Woong Choi¹,², and Yong-Ho Park¹,²

¹Department of Otolaryngology-Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Korea
²Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Chungnam National University, Daejeon, Korea

Introduction

Hematoma of the ear typically occurs in sports-related injuries, particularly among wrestlers and boxers. Simultaneous application of blunt and shearing forces to the pinna can result in disruption of the perichondrium’s attachment to the underlying cartilage with subsequent accumulation of blood in the subperichondrial space of the pinna. Appropriate management of auricular hematoma should aim toward achieving effective evacuation of the hematoma, prevention of recurrence, and a good cosmetic outcome. If not treated properly, it can cause a deformity known as ‘cauliflower ear’ or ‘wrestler’s ear.’ There is no consensus on the best treatment method, and various surgical techniques have been described [1-8]. We report a case of othematoma that was inappropriately treated.

Case Report

A 13-year-old female patient presented with a one-month history of painful swelling on her left ear. Her ear injury occurred when she was dashed against a wall. She was being treated by a general physician for three weeks prior to her admission, but the symptoms did not improve. She had a medical history of hydrocephalus, epilepsy, and mental retardation. No history of any coagulopathy was evident. Typical auricular landmarks were lost because of marked swelling with erythema. A 2-cm long previous incision scar was observed over the antihelix (Fig. 1). Needle aspiration failed to yield any diagnostic material.

Surgery was opted as the treatment plan. An incision was made over the antihelix along the previous incision site and the subcutaneous flap was elevated off the lesion (Fig. 2). While the skin flap was being elevated, numerous fragments of spongy material of various sizes were observed between the subcutaneous tissue and cartilage (Fig. 3). The hematoma, granulation tissue, fibrous tissue, fibrocartilaginous cartilage, and foreign material were removed by curettage and debriement. No packing materials or hemostatic agents were ap-
plied in the evacuated wound pocket. Skin was sutured with 3-0 nylon. Two Penrose drains were placed in the subperichondrial layer and bolsters were placed on the anterior and posterior aspect of the auricle, fixed with through-and-through-sutures (Fig. 4).

Histopathologic examination of the debrided material showed mesh-like membranous foreign bodies with proliferative granulation tissue surrounded by inflammatory cells (Fig. 5). At two weeks follow-up, her affected ear had healed with desirable cosmetic result and no evidence of hematoma recurrence was observed (Fig. 6).

**Discussion**

A conventional surgical intervention for othematoma begins with a local field block using 2% lidocaine with epinephrine 1:100,000. Drainage is performed via a surgical incision on the helical rim or margin of the most prominent area followed by removal or irrigation of the extravasated blood and fluids. To prevent recurrence, a drain, sutures, or adequate compression using a splint or bolster should be applied for several days to inhibit dead space formation [2-9]. Recently, steroid or OK-432 application has also been considered as an option [1,10-12] and a previous report demonstrated good results with fibrin glue hemostatic material [13].

There are several synthetic biomaterials that can be used for bleeding control during surgical procedures. These may be used for hemostasis, as skin adhesive, or packing material. In order to use these materials appropriately, it is important to know the physical characteristics or details of these materials (Table 1). They can be classified as absorbable or non-absorbable materials and accordingly, may be used either internally or externally. For example, a representative hemostatic material called fibrin sealant (TISSEEL, Baxter International Inc., Deerfield, IL, USA) is a liquid compound that can be used as a supportive material for bleeding control after applying a surgical suture or ligation. Even though this fibrin sealant completely resorbs in 10 to 14 days, it should not be used in a way that it is directly in contact with the circulatory system or highly vascularized tissue, as it may result in a thromboembolic event. Furthermore, the company has recommended minimal use of this material. Another material called hydroxylated polyvinyl acetate (Merocel®, Medtronic ENT, Jacksonville, FL, USA) is an artificial sponge tampon with micro-oxidized cellulose. It is widely used for bleeding control in epistaxis, septal surgery, and sinus surgery. It can offer structural support for the prevention of postoperative stenosis in rhinoplasty. It has also been used as an ear wick in external auditory canal trauma. This material is soft and has a high capacity to absorb water with good elasticity but clinicians should be aware that it is non-absorbable and does not exhibit any antimicrobial properties. Extra caution should be taken before its use in cases...
with pre-existing infection because of the possibility of toxic shock syndrome. This kind of hemostatic packing material should not be used internally because it may not be easily removed. It is important that clinicians are aware of the advantages and disadvantages of the various medical biomaterials before their use.

In this case, a less well-informed general physician inappropriately treated an auricular hematoma by leaving a non-absorbable hemostatic material in a closed cavity that eventually lead to chondritis and cartilage necrosis. It is crucial that doctors have a proper understanding of the hemostatic materials before use.

In conclusion, appropriate management of auricular hematoma should be aimed at achieving effective evacuation of the hematoma, preventing recurrence, and providing a good cosmetic outcome. Doctors should be aware of the characteristics and details of the various hemostatic materials before use, to prevent adverse irreversible sequelae or complications.

Acknowledgments

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) (NRF-2018R1A2B2005022 and 2019M3E5D1A02068573).

Conflicts of interest

The authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Yong-Ho Park. Funding acquisition: Yong-Ho Park. Investigation: Yoonjoong Kim and Yong-Ho Park. Project ad-
An Inappropriately Treated Othematoma

An Inappropriately Treated Othematoma

ministration: Yong-Ho Park. Supervision: Jin Woong Choi and Yong-Ho Park. Visualization: Yoonjoong Kim and Yong-Ho Park. Writing—original draft: Yoonjoong Kim and Yong-Ho Park. Writing—review & editing: Yoonjoong Kim. Approval of final manuscript: all authors.

ORCID iDs

Yoonjoong Kim https://orcid.org/0000-0002-9589-9244
Jin Woong Choi https://orcid.org/0000-0003-3101-6841
Yong-Ho Park https://orcid.org/0000-0003-2106-3791

REFERENCES

4) Rah YC, Park MH. Use of silastic sheets with mattress-fasion su-
5) Shakeel M, Vallamkondu V, Mountain R, Hussain A. Open surgi-
cal management of auricular haematoma: incision, evacuation and mattress su-
11) Brickman K, Adams EZ, Akpunou P, Adams SS, Zohn SF, Guin-
12) Lee SY, Han SA, Park MH, Kim YH. Clinical implications of intra-
lesional steroid injections in the management of othematoma. La-

Table 1. Various hemostatic materials

<table>
<thead>
<tr>
<th>Usage</th>
<th>Product name</th>
<th>Ingredient or component</th>
<th>Type</th>
<th>Absorbability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemostatics</td>
<td>Gelfoam® (Pfizer, NY, NY)</td>
<td>Gelatin</td>
<td>Sponge, powder</td>
<td>(4-6 weeks)</td>
</tr>
<tr>
<td></td>
<td>Surgifoam® (Ethicon Inc., Somerville, NJ)</td>
<td>Gelatin+human thrombin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gelfoam plus® (Baxter International Inc., Deerfield, IL)</td>
<td>Microfibrillar collagen</td>
<td>Sponge, sheet, flour</td>
<td>Absorbable</td>
</tr>
<tr>
<td></td>
<td>Avitene® (Becton, Dickinson and Co., Franklin Lakes, NJ)</td>
<td>Aprotinin+calcium chloride+lyophilized fibrinogen</td>
<td>Liquid (frozen)</td>
<td>Absorbable</td>
</tr>
<tr>
<td></td>
<td>Helistat® (Integra Lifesciences corp., Plainsboro Township, NJ, USA)</td>
<td>concentrate+thrombin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgicel® (Ethicon Inc., Somerville, NJ, USA)</td>
<td>Oxidized cellulose</td>
<td>Sheet, strip</td>
<td>(1-6 weeks)</td>
</tr>
<tr>
<td></td>
<td>Oxyce® (Parke-Davis, Detroit, MI, USA)</td>
<td>Gelatin+human thrombin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tissue (Baxter International Inc., Deerfield, IL, USA)</td>
<td>Microfibrillar collagen</td>
<td>Sponge, sheet, flour</td>
<td>Absorbable</td>
</tr>
<tr>
<td></td>
<td>Greenplast kit (GC Pharma Corp., Yongin, Korea)</td>
<td>Oxidized cellulose</td>
<td>Sheet, strip</td>
<td>(1-6 weeks)</td>
</tr>
<tr>
<td></td>
<td>Crosseal® (Omrix Biopharmaceuticals Inc., New York, NY, USA)</td>
<td>Oxidized cellulose</td>
<td>Sheet, strip</td>
<td>(1-6 weeks)</td>
</tr>
<tr>
<td></td>
<td>Evicel® (Ethicon Inc., Somerville, NJ, USA)</td>
<td>Oxidized cellulose</td>
<td>Sheet, strip</td>
<td>(1-6 weeks)</td>
</tr>
<tr>
<td>Skin adhesives</td>
<td>Dermabond® (Ethicon Inc., Somerville, NJ, USA)</td>
<td>2-octyl-cyanoacrylate</td>
<td>Liquid</td>
<td>Non-absorbable</td>
</tr>
<tr>
<td></td>
<td>Liquiband® (Advanced Medical Solutions, Winsford, UK)</td>
<td>n-butyl-2-octyl-cyanoacrylate</td>
<td>Liquid</td>
<td>Non-absorbable</td>
</tr>
<tr>
<td></td>
<td>Histoacryl® (B. Braun, Melsungen, Germany)</td>
<td>n-butyl-2-octyl-cyanoacrylate</td>
<td>Strip, glue</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukosan® Skinlink (BSN Medical GmbH, Hamburg, Germany)</td>
<td>2-octyl-cyanoacrylate</td>
<td>Strip, glue</td>
<td></td>
</tr>
<tr>
<td>Parking materials</td>
<td>Merocel® (Medtronic ENT, Jacksonville, FL, USA)</td>
<td>Hydroxylated polyvinyl acetate</td>
<td>Sponge</td>
<td>Non-absorbable</td>
</tr>
<tr>
<td></td>
<td>Merocel® hemoX® (Medtronic ENT, Jacksonville, FL, USA)</td>
<td>Hydroxylated polyvinyl acetate+micro-dispersed oxidized cellulose</td>
<td>Sponge, strip</td>
<td>(5-10 days)</td>
</tr>
<tr>
<td></td>
<td>NasoPore® (Stryker, Kalamazoo, MI, USA)</td>
<td>Synthetic polyurethane</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>